- Treating intellectual property as an investment, and subjecting it to treaty arbitration, can have undesirable impact
- The expanding universe of IP
- CCI to investigate Swiss drugmaker Roche over breast cancer biosimilar
- Indian competition commission issues a path breaking order on abuse of dominant position in pharmaceuticals
- TPP May Be Dead but Big Pharma’s Still Getting Away with Murder
Category Archives: Hepatitis C
According to the WHO, India is a high burden country for HCV and has about 12-18 million chronically infected patients, most are unaware of their infection status and a third of whom will develop liver cirrhosis or hepatocellular carcinoma, which … Continue reading
A health advocacy group voiced its opposition Tuesday to a patent application for hepatitis C medicine, Sofosbuvir, filed with the Department of Intellectual Property’s Patent Office, which the group said was unjustified. If approved, the drug patent would bar fair … Continue reading
Source: Business World The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral medicines, which are currently sold at very high prices Patient and healthcare aid groups, including I-MAK and Delhi Network of … Continue reading
By Rupali Mukherjee, The Times of India MUMBAI: Healthcare aid and patient groups have come together in patent courts to fight against “abusive strategies” of Big Pharma, to ensure access to affordable treatment in hepatitis C. The Initiative for Medicines, … Continue reading
Source: MSF Access Campaign New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. … Continue reading
The World Health Organization (WHO) recently reported that over one million people in low- and middle-income countries have been treated with a revolutionary new cure for hepatitis C since its introduction two years ago.
(Paris, October 5th 2016) European Patent Office (EPO) has taken its decision following Doctors of the World – Médecins du Monde (MdM) patent opposition on Gilead Sciences’ Sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent.